IGF1 and atypical Rett syndrome: Indeed, trofinetide (DAYBUETM), an oral small molecule synthetic analog of an N-terminal tripeptide derivative of IGF-1, has been approved by the US Food and Drug Administration (FDA) as the first drug for the treatment of Rett syndrome (RTT) to improve social communication [46].